How often anti-amyloid antibodies cause imaging abnormalities

Design

Systematic review and meta-analysis of 21 phase 3 randomised trials

Population

12,610 patients with early Alzheimer's disease on anti-amyloid monoclonal antibodies

Primary outcome

Incidence and severity of amyloid-related imaging abnormalities

Effect

ARIA-E 5.4%, ARIA-H 10.3%; ApoE4 homozygotes odds ratio 5.12 for ARIA-E

As anti-amyloid monoclonal antibodies enter practice for early Alzheimer's disease, internists increasingly field questions about their safety and share in monitoring. This meta-analysis pooled 21 phase 3 randomised trials and 12,610 patients to size the problem of amyloid-related imaging abnormalities (ARIA).

Pooled incidence was 5.4% for the oedema type (ARIA-E) and 10.3% for the haemorrhage type (ARIA-H), with most cases asymptomatic and radiographically mild to moderate. Risk concentrated in ApoE4 carriers: homozygotes had roughly five times the odds of ARIA-E, and higher antibody doses and baseline microhaemorrhages also raised risk. ApoE4 carriage was linked to symptomatic and more severe imaging changes too.

The practical message is that ARIA is common on imaging but usually silent, and that ApoE4 genotype and baseline MRI should inform the conversation before starting therapy. Internists are well placed to flag anticoagulation, uncontrolled hypertension and genotype when these patients are co-managed.

• Meta-analysis of 21 phase 3 trials and 12,610 patients on anti-amyloid monoclonal antibodies.
• ARIA-E (oedema) occurred in 5.4% and ARIA-H (haemorrhage) in 10.3%, mostly asymptomatic.
• ApoE4 homozygotes had about five times the odds of ARIA-E (odds ratio 5.12).
• Higher antibody dose and baseline microhaemorrhages also raised ARIA risk.
• Check ApoE4 genotype and baseline MRI, and review anticoagulation, before therapy.

Why it matters

It turns a feared side-effect into a stratifiable risk that genotype and baseline imaging can anticipate.

Don't overread it

Most ARIA is asymptomatic and mild on imaging; these figures are a monitoring signal, not a reason to withhold therapy from an eligible patient.

The statistics, in plain English

A 10.3% pooled incidence means about one in ten patients shows a haemorrhage-type change on MRI, but most never develop symptoms. An odds ratio of 5.12 for ApoE4 homozygotes is a large relative increase that justifies genotype-guided counselling and monitoring.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.